Rhumbline Advisers Acquires Shares of 13,825 Helius Medical Technologies Inc (HSDT)
Rhumbline Advisers acquired a new stake in shares of Helius Medical Technologies Inc (OTCMKTS:HSDT) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 13,825 shares of the company’s stock, valued at approximately $132,000. Rhumbline Advisers owned 0.06% of Helius Medical Technologies as of its most recent SEC filing.
A number of other hedge funds have also modified their holdings of HSDT. Pier 88 Investment Partners LLC purchased a new position in Helius Medical Technologies during the second quarter valued at approximately $185,000. Pembroke Management LTD purchased a new position in Helius Medical Technologies during the second quarter valued at approximately $10,268,000. Finally, Isthmus Partners LLC increased its holdings in Helius Medical Technologies by 67.8% during the second quarter. Isthmus Partners LLC now owns 236,934 shares of the company’s stock valued at $2,256,000 after buying an additional 95,695 shares during the period.
Separately, BTIG Research reissued a “neutral” rating and set a $14.00 price objective on shares of Helius Medical Technologies in a report on Tuesday, June 19th.
Helius Medical Technologies (OTCMKTS:HSDT) last issued its quarterly earnings data on Thursday, August 9th. The company reported ($0.77) earnings per share (EPS) for the quarter.
About Helius Medical Technologies
Helius Medical Technologies, Inc is a medical technology company focused on neurological wellness. The Company focuses on developing, licensing or acquiring non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company is engaged in the development of its product, the portable neuromodulation stimulator (PoNS) device.
Recommended Story: What is a closed-end mutual fund (CEF)?
Receive News & Ratings for Helius Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helius Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.